Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. Considering these observations, we collected data from 21 CLL referral centers in Italy to better understand the attitude toward choice and management of venetoclax- based treatment during the pandemic, also in the light of ASH recommendations.
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia
Visentin, Andrea;Quaresmini, Giulia;Sanna, Alessandro;Ferrarini, Isacco;
2022-01-01
Abstract
Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. Considering these observations, we collected data from 21 CLL referral centers in Italy to better understand the attitude toward choice and management of venetoclax- based treatment during the pandemic, also in the light of ASH recommendations.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
How COVID 19 pandemic changed our attitude to venetoclax based treatment in chronic lymphocytic leukemia.pdf
solo utenti autorizzati
Tipologia:
Versione dell'editore
Licenza:
Creative commons
Dimensione
966.46 kB
Formato
Adobe PDF
|
966.46 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
